No differentiation for Roche's degrader
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Astra ditches a Duo
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Pfizer downgrades disitamab again
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
Datroway and Trodelvy's new breast cancer battle
But the Astra/Daiichi ADC stumbles in lung cancer.
